Healthcare outperformed on a risk-off day, XLV +1.3% while XBI, NBI and BBC each slipped 0.7%. The day's big single-name move was Moderna, down 21% after INTerpath-001 data leaked Thursday morning and were posted that afternoon, with Avalo off about 36% on AbbVie's HS readout.

AI-capex doubts hit tech: Meta fell 7.0% on its first cash outflow in over a decade and the SOX lost 6.7%, leaving NDX (2.9%) and the S&P (1.2%) lower, while the Dow finished flat (+0.02%) with P&G +5.6% and Lockheed +7.0% and RUT edged up 0.1%; the 10Y slipped back below 5%, Houthi strikes on Saudi targets pushed crude to a five-month high, and 8:30 ET jobless claims printed 194k, a three-month low.

Gilead is acquiring worldwide rights to HCXT-2001, Shanghai-based PepStar's Phase 1 oral macrocyclic peptide IL-23R inhibitor for IBD and psoriasis, for $1.275B in cash upfront; milestones and royalties were not disclosed. Announced after Thursday's close, the deal is expected to close in Q4 and cut Q4 EPS by $0.79-0.83.

Why it matters: Big cash for a Phase 1 asset with no published clinical data (Citi's Geoffrey Meacham), and it prices oral IL-23R as a franchise rather than a project after J&J's Icotyde showed a peptide pill can compete with injectables in psoriasis. Gilead's stated plan is a daily oral IBD regimen, HCXT-2001 alone or paired with emvistegrast, the oral α4β7 that posted 31% versus 8% clinical remission at week 12 in Monday's Phase 2 UC data.

Source: Endpoints

More: Reuters

Detailed INTerpath-001 data, pulled forward to Thursday after an ESMO embargo breach, showed intismeran autogene plus Keytruda cut melanoma recurrence-or-death risk 42% versus Keytruda alone (RFS HR 0.58; 24-month RFS 82.2% vs 70.0%). DMFS HR was 0.62 (88.5% vs 80.2%); grade 3-5 treatment-related AEs ran 14.2% vs 13.4%. Full presentation Saturday at ESMO.

Why it matters: August gave the topline; Thursday gave the numbers the market had been pricing blind. Analysts had modelled an RFS hazard ratio as low as 0.5 off the Phase 2 (RBC: 0.51), so 0.58 sits inside management's 0.5-0.8 "meaningful" range but outside the bull case. The bigger gap is distant metastasis, the endpoint Moderna had pitched as decisive: a 38% risk reduction against 65% in the Phase 2 primary analysis. Moderna fell 21% to $193.65 and Merck about 1%. BMO said the data cannot carry elevated expectations; RBC sees approval as likely and commercial success as far less certain. A stock still up 525% this year now needs overall survival and the non-melanoma readouts to do the lifting.

Source: STAT

More: Fierce Biotech; BioSpace

Treasury proposed adding biotech to the COINS Act outbound-investment regime, classing "pharmaceutical compounds" (small molecules through cell and gene therapies and antibodies) as prohibited technology. US equity stakes, convertible debt, greenfield investment, JVs and certain LP commitments in China biotech would be barred; asset licensing for cash, milestones and royalties falls outside scope. Comments are due 7 December.

Why it matters: The text targets capital and largely spares BD. Pure licensing, the structure behind BMS's up-to-$15.2B Hengrui pact, looks safe. Equity does not: Pfizer's $100M stake in 3SBio would be prohibited, which shuts US VC rounds into Chinese biotechs and threatens the NewCo model where a Chinese licensor keeps equity, because an anti-evasion clause can reach NewCos below the 50% Chinese-ownership line. Co-development pacts with shared P&L sit in a grey zone, Pfizer-Innovent's $10.5B deal included, since Treasury left "joint venture" undefined. Grandfathering covers only deals done before 18 December 2025. BIO's John Crowley is already pushing to narrow the scope before the 7 December comment deadline.

Source: Endpoints

More: Fierce Biotech; STAT

AbbVie's lutikizumab (IL-1α/β) met the INTREPID Phase 3 primary in hidradenitis suppurativa (n≈1,400; HiSCR75 31.4% vs 23.4% at week 16), well short of H.C. Wainwright's 45-50% bar; filings 2H27, Avalo down about 36%. — Fierce Biotech

AstraZeneca's Ultomiris won FDA accelerated approval in IgA nephropathy, the first C5 inhibitor in the setting, on a 43.4% proteinuria reduction vs placebo at 34 weeks in I CAN; week-106 eGFR data to confirm. — Fierce Pharma

FDA accepted Biohaven's resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia a year after rejecting it; an advisory committee is planned and a decision is expected in 1Q27. — BioPharma Dive

Roche's Q3 sales rose 7% to CHF16.1B, ahead of the CHF15.8B consensus, and it held its mid-single-digit 2026 outlook; Xolair's CHF848M missed estimates after a US biosimilar launched this month. — BioPharma Dive

Roche dropped Poseida's off-the-shelf CAR-T RG6540 in a pipeline trim, while its CEO said he has "absolutely not" soured on the $1.5B Poseida buy. — Fierce Biotech

Pfizer and Valneva's detailed VALOR Lyme vaccine data were mixed, with one of two efficacy analyses narrowly missing; the gap likely came down to a single case. — Endpoints

HUYABIO said HBI-8000 plus nivolumab cut the risk of progression or death 27% in a Phase 3 in advanced melanoma. — PR

Harbour BioMed won China NMPA approval for subcutaneous batoclimab (FcRn) in generalized myasthenia gravis. — PR

Compounder Apothecary Pharma recalled 22 lots of copycat tirzepatide (Zepbound) in a Class II action, saying it could not guarantee the product's safety. — BioPharma Dive

Gilead / PepStar (Shanghai) — asset acquisition of HCXT-2001 (oral IL-23R peptide, Phase 1), worldwide rights, $1.275B cash upfront; close Q4 2026. — Endpoints

Menarini's Stemline / Georgiamune — exclusive worldwide licence to GIM-621, a preclinical oral small-molecule immunotherapy for solid tumors, $45M upfront, up to $1.1B total. — Fierce Biotech

Celltrion / Kaigene — exclusive global licence to KG013, a half-life-extended anti-APRIL antibody led in IgA nephropathy, up to $580.5M plus royalties, upfront undisclosed; Celltrion's third Kaigene asset. — Fierce Biotech

EQT / QIAGEN — recommended all-cash take-private at €46.50/share, ~€10.8B ($12.1B) EV incl. net debt; 50%+1 minimum acceptance, close mid-2027. — PR

Arctic Therapeutics (Reykjavík/Philadelphia) — oversubscribed $21.5M round led by Pekron, Sanos Group, Kaldbakur and Landvættir, after a ~$31M Series A; funds AT-002 (SOCS1 peptide mimetic, autoimmune uveitis) and AT-003 (CLEC16A-linked mitophagy modulator) toward the clinic (announced Wed 21 Oct). — PR

Arcus Biosciences (RCUS) — priced $250M follow-on, 14.29M shares at $17.50 (+15% option), Jefferies/Leerink/TD Cowen/Evercore/Mizuho; closes 23 Oct, after its ARC-20 casdatifan investor event. — Endpoints

Mitapivat's phase 3 RISE UP study in sickle cell disease landed in The Lancet. — Lancet

Nature Biotechnology published ALTER, a human-protein RNA editor built around Argonaute 2. — Nature Biotech

NEJM published final phase 3 analysis of sibeprenlimab in IgA nephropathy. — NEJM

NEJM also published final phase 3 efficacy analysis of atacicept in IgA nephropathy. — NEJM